EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2023


#285713

51pages

GlobalData

$ 3995

In Stock


Prostate cancer is a malignant tumor that forms in the tissues of the prostate, a gland in the male reproductive system found below the bladder and in front of the rectum. Although prostate cancer cases have been reported in all age groups, the majority of cases occur in men over the age of 65 years. Prostate cancer is the second most common cancer in men worldwide. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of all the cancers diagnosed in men (IARC, 2014).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for prostate cancer in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) in these markets.

In 2013, there were a total of 813,462 diagnosed incident cases of prostate cancer in the 9MM. GlobalData epidemiologists forecast that the diagnosed incident cases in the 9MM will increase to 1,106,349 cases by 2023 at an Annual Growth Rate (AGR) of 3.60%. All markets will see an increase in the number of cases, with AGRs ranging from 0.71% (Germany) to 8.66% (Brazil). The 9MM had an estimated 3,381,581 diagnosed five-year prevalent cases of prostate cancer in 2013. The number of diagnosed five-year prevalent cases will increase over the next decade to 4,618,451 diagnosed prevalent cases by 2023 at an AGR of 3.66%.

Brazil appears to be a market of concern, with a rapidly increasing incidence and prevalence of prostate cancer. GlobalData epidemiologists calculated that Brazil will have the highest AGR in diagnosed incident cases among the 9MM (8.66%), as well as the highest AGR in five-year diagnosed prevalent cases (8.98%).

Scope

  • The Prostate Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for prostate cancer in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) and clinical stage at diagnosis in these markets. The report also provide a forecast for the diagnosed five-year prevalent cases of prostate cancer segmented by castration resistance status and bone metastases status.
  • The prostate cancer epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and clinical stage at diagnosis that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Report 8

3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 US 13
3.3.2 5EU 14
3.3.3 Japan, Brazil, and Canada 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 16
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods 23
3.5 Epidemiological Forecast for Prostate Cancer (2013-2023) 26
3.5.1 Diagnosed Incident Cases of Prostate Cancer 26
3.5.2 Age-Specific Diagnosed Incident Cases of Prostate Cancer 28
3.5.3 Age-Standardized Diagnosed Incidence of Prostate Cancer 30
3.5.4 Clinical Stage at Diagnosis 32
3.5.5 Diagnosed Five-Year Prevalent Cases of Prostate Cancer 33
3.5.6 Diagnosed Five-Year Prevalent Cases of CRPC 34
3.5.7 Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients 36
3.6 Discussion 38
3.6.1 Epidemiological Forecast Insight 38
3.6.2 Limitations of the Analysis 39
3.6.3 Strengths of the Analysis 40

4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 46
4.2.1 Epidemiologists 46
4.2.2 Reviewers 46
4.2.3 Global Director of Therapy Analysis and Epidemiology 47
4.2.4 Global Head of Healthcare 48
4.3 About GlobalData 49
4.4 About EpiCast 49
4.5 Disclaimer 50

Table 1: Risk Factors and Comorbidities for Prostate Cancer 11
Table 2: 9MM, Sources of Prostate Cancer Diagnosed Incidence Data 16
Table 3: 9MM, Sources of Data for the Clinical Stage of Prostate Cancer at Diagnosis 17
Table 4: 9MM, Sources of Prostate Cancer Diagnosed Five-Year Prevalent Cases Data 18
Table 5: 9MM, Sources of CRPC Diagnosed Five-Year Prevalent Cases Data 19
Table 6: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages 40 Years, N, 2013-2023 27
Table 7: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, Row (%), 2013 29
Table 8: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages 40 Years, 2013-2023 33
Table 9: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages 40 Years, 2013-2023 35
Table 10: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages 40 Years, 2013-2023 37

Figure 1: 9MM, Historical Age-Standardized Prostate Cancer Diagnosed Incidence (Cases per 100,000 Population), 1998-2007 13
Figure 2: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages 40 Years, N, 2013-2023 28
Figure 3: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, 2013 30
Figure 4: 9MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Ages 40 Years, 2013 31
Figure 5: 9MM, Percentage Distribution of Incident Cases of Prostate Cancer By Clinical Stage at Diagnosis, Ages 40 Years 32
Figure 6: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages 40 Years, 2013-2023 34
Figure 7: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages 40 Years, 2013-2023 36
Figure 8: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages 40 Years, 2013-2023 37